⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AUTL News
Autolus Therapeutics plc American Depositary Share
Autel onthult strategische verschuiving op CES 2026: bouwen aan de AI-aangedreven infrastructuur van toekomstige steden
businesswire.com
AUTL
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle TM Platform
businesswire.com
AUTL
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform
globenewswire.com
AUTL
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
prnewswire.com
GTBP
REGN
GMAB
AUTL
LYEL
Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025
globenewswire.com
AUTL
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
globenewswire.com
AUTL
Autolus Therapeutics Appoints Ryan Richardson to Board of Directors
globenewswire.com
AUTL
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹
globenewswire.com
AUTL
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
globenewswire.com
AUTL
Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
globenewswire.com
AUTL